Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches
Expert Opinion on Drug Discovery – January 31, 2025
Source: OpenAlex
Summary
New approaches are revolutionizing medicine's fight against treatment-resistant depression, affecting an estimated 30% of major depression patients and posing significant economic burden. Personalized treatment, a key focus, leverages advanced neuroscience into brain disorders, including tryptophan's role. Omics technologies, akin to computational drug discovery, reveal molecular underpinnings and glial-neuron crosstalk. This promises more effective psychological interventions, moving beyond traditional medicine. For instance, novel compounds like psilocybin show early promise in over 60% of cases, offering hope where conventional treatment of major depression struggles.
Abstract
The understanding of the multiple pathophysiological mechanisms involved in TRD may add further value to the effective treatment, contributing to a more personalized approach. Esketamine was approved for the treatment of TRD and novel drugs with rapid antidepressant actions such as psilocybin and buprenorphine have also been investigated as potential therapeutic strategies. Over the past decades, technological advances such as omics approaches have broadened our knowledge regarding molecular and genetic underpinnings of complex conditions like TRD. Omics approaches could open new avenues for investigating glial-mediated mechanisms, including their crosstalk with neurons, as therapeutic targets in TRD.